Paxlovid Lowers Risk of Long COVID - MedicineNet Health News

  • 📰 MedicineNet
  • ⏱ Reading Time:
  • 50 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 23%
  • Publisher: 51%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

Paxlovid effective against long COVID, study finds.

The research team studied the cases of 56,000 veterans who had contracted the virus. More than 9,000 patients were treated with Paxlovid within five days of infection between March 1 and June 30.

The patients had an average age of 65 and had at least one health issue that put them at higher risk for a more severe COVID, such as older age,While the study only included VA system patients who were mostly white and male, they were a mix of unvaccinated, vaccinated and boosted individuals, as well as those who had previously been infected with“The totality of evidence suggests the need to improve uptake and utilization of nirmatrelvir in the acute phase as a means of not only preventing...

Paxlovid, made by the drug company Pfizer, can be used by people ages 12 and up. Though it's said to work best within five days of symptoms starting, it's not clear whether altering the dose to take higher amounts of the drug or to take it for more days would have more impact,The National Institutes of Health plans to study using Paxlovid in patients who already have long COVID to understand any impact that may have.Copyright © 2022 HealthDay. All rights reserved.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 575. in HEALTH

Health Health Latest News, Health Health Headlines